A kind of pharmaceutical composition containing ginkgolide B and phosphodiesterase inhibitor and its preparation method and application

A technology of phosphodiesterase and ginkgolide, which is applied in the direction of drug combinations, medical preparations containing active ingredients, and pharmaceutical formulas, can solve the problems of small side effects, high cost, and high price, and reduce the amount of use , the effect of a clear mechanism of action

Active Publication Date: 2019-03-15
CHENGDU BAIYU PHARMA CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Ginkgolide B is an active ingredient extracted from the natural medicine Ginkgo biloba. It has few side effects and strong activity. It is the strongest platelet activating factor antagonist found so far, but the price is high, and the cost of clinical use is too high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition containing ginkgolide B and phosphodiesterase inhibitor and its preparation method and application
  • A kind of pharmaceutical composition containing ginkgolide B and phosphodiesterase inhibitor and its preparation method and application
  • A kind of pharmaceutical composition containing ginkgolide B and phosphodiesterase inhibitor and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Ginkgolide B10 parts

[0040] Cilostazol 50 parts

[0041] Pharmaceutically acceptable conventional excipients

[0042] After the above-mentioned raw materials are mixed, a pharmaceutically acceptable conventional auxiliary material is added to prepare a pill according to a conventional process.

Embodiment 2

[0044] Ginkgolide B10 parts

[0045] Cilostazol 100 parts

[0046] Pharmaceutically acceptable conventional excipients

[0047] After mixing the above-mentioned raw materials, add conventional pharmaceutically acceptable auxiliary materials to prepare capsules or soft capsules according to conventional processes.

Embodiment 3

[0049] Ginkgolide B1 part

[0050] Cilostazol 10 parts

[0051] Pharmaceutically acceptable conventional excipients

[0052] After the above raw materials are mixed, add pharmaceutically acceptable conventional adjuvants and prepare tablets according to conventional techniques.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition containing ginkgolide B. The pharmaceutical composition comprises the ginkgolide B and phosphodiesterase inhibitor. The invention further provides a preparation method and application of the pharmaceutical composition. The pharmaceutical composition has the advantages that the ginkgolide B and the phosphodiesterase inhibitor are combined to achieve a synergic effect, and the pharmaceutical composition is excellent in platelet aggregation inhibiting effect, low in side effect and promising in clinical application prospect; the pharmaceutical composition is novel in prescription, simple in component, clear in action mechanism, evident in curative effect, less prone to tolerance generating and capable of achieving large-scale industrial production.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing ginkgolide B. Background technique [0002] Both cilostazol and sildenafil are phosphodiesterase inhibitors, which can inhibit platelet aggregation and have antithrombotic effect. [0003] Cilostazol, Chinese name: 6-[4-(1-cyclohexyl-1H-pentazol-5-yl)butoxy]-3[1],4-dihydro-2(1H)-quinolone , molecular formula: C 2 0H 2 7N 5 o 2 Molecular weight: 369.4607 Molecular structure: [0004] [0005] Cilostazol can inhibit platelet aggregation, has antithrombotic effect, and is used to treat local diseases such as chronic arterial occlusive ulcer, pain and cold sensation. The main adverse reactions are headache, dizziness and palpitation, etc. Some patients may have high blood pressure, followed by abdominal distension, nausea, vomiting, stomach discomfort, abdominal pain and other gastrointestinal symptoms. Abnormal uric acid value, occasional allergic reactions, including rash, itching...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4709A61K31/519A61K45/00A61P7/02A61K31/365
Inventor 孙毅
Owner CHENGDU BAIYU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap